Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Two Phase I studies found that a single 10 mg dose of iclepertin raised drug exposure in severe renal and ...
